NEO-201 and IL-15 Combination Therapy Data for Endometrial and Ovarian Cancer

A 14.2 KB document details in vitro and in vivo experiments combining monoclonal antibody NEO-201 with IL-15 cytokine. Jamie Hur authored this research, posted on figshare under a CC-BY-4.0 license and last updated in March 2026. The study investigates overcoming immunotherapy resistance in human endometrial and ovarian cancer cell lines.

Use Cases

• Analyzing the efficacy of combination immunotherapy based on in vitro ADCC assay results described in the document.
• Studying the role of O-glycans in cancer cell resistance based on the described target antigen for NEO-201.
• Designing preclinical studies for NK cell-based therapies based on the described combination with IL-15.
• Investigating mechanisms to enhance monoclonal antibody activity based on the described use of IL-15 to boost NK cells.

Strengths

• Document is shared under a permissive CC-BY-4.0 license, allowing for reuse and redistribution.
• The research context is described in detail, including specific cell lines (endometrial, ovarian) and mechanisms like ADCC and CDC.

Limitations

• The dataset is a 14.2 KB DOCX file, indicating a very limited scope, likely a summary table or manuscript rather than raw experimental data.
• Column-level documentation and sample data are unavailable, making field semantics and structure unknown.
• Row count is unknown, which may limit suitability assessment for quantitative analysis.

Provenance

Source

figshare

Collection Method

Likely contains summarized experimental results from in vitro cell line treatments and in vivo mouse model studies.

Freshness

Last updated 2026-03-17 13:06:54; freshness should be verified.